Seven-year efficacy of RTS, S/AS01 malaria vaccine among young african children

New England Journal of Medicine

Volumn 374, Issue 26, 2016, Pages 2519-2529

  Olotu, Ally ^a,b   Fegan, Gregory ^a,c   Wambua, Juliana ^a   Nyangweso, George ^a   Leach, Amanda ^d   Lievens, Marc ^d   Kaslow, David C ^e   Njuguna, Patricia ^a   Marsh, Kevin ^a,c   Bejon, Philip ^a,c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GSK   (Belgium)

^e PATH ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

AFRICAN; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALARIA FALCIPARUM; MENINGITIS; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; VACCINATION; CLINICAL TRIAL; FEMALE; FOLLOW UP; IMMUNOLOGY; INFANT; INFORMATION PROCESSING; INTENTION TO TREAT ANALYSIS; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; MALE; PARASITEMIA; PROPORTIONAL HAZARDS MODEL;

DATASETS AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INTENTION TO TREAT ANALYSIS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PARASITEMIA; PLASMODIUM FALCIPARUM; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84976509278     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1515257     Document Type: Article

References (16)

1. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386: 31-45.
2. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368:1111-20.
3. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359: 2521-32.
4. Bejon P, Williams TN, Nyundo C, et al. A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots. Elife 2014; 3: e02130.
5. Olotu A, Fegan G, Wambua J, et al. Estimating individual exposure to malaria using local prevalence of malaria infection in the field. PLoS One 2012; 7(3): e32929.
6. Akl EA, Briel M, You JJ, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ 2012; 344: e2809.
7. RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014; 11(7):e1001685.
8. Noor AM, Kinyoki DK, Mundia CW, et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet 2014; 383:1739-47.
9. Bejon P, Cook J, Bergmann-Leitner E, et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS, S/AS01E on blood stage immunity in young children. J Infect Dis 2011; 204: 9-18.
10. Trape JF, Tall A, Diagne N, et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 2011; 11: 925-32.
11. Menendez C, Kahigwa E, Hirt R, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 1997; 350:844-50.
12. Oyediran AB, Topley E, Osunkoya BO, et al. Severe morbidity among children in a trial malaria chemoprophylaxis with pyrimethamine or chloroquine in Ibarapa, Nigeria. Afr J Med Med Sci 1993; 22: 55-63.
13. Senn N, Rarau P, Stanisic DI, et al. Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial. PLoS Med 2012; 9(3):e1001195.
14. Grobusch MP, Gabor JJ, Aponte JJ, et al. No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon. J Infect Dis 2009; 200: 1658-61.
15. Odhiambo FO, Hamel MJ, Williamson J, et al. Intermittent preventive treatment in infants for the prevention of malaria in rural western Kenya: a randomized, double-blind placebo-controlled trial. PLoS One 2010; 5(4):e10016.
16. Campo JJ, Aponte JJ, Skinner J, et al. RTS, S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and bloodstage parasites. Mol Cell Proteomics 2015; 14:519-31.